Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Thomas Powles, Se Hoon Park, Eric Voog, Claudia Caserta, Begoña Pérez-Valderrama, Howard Gurney, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Andy Blake-Haskins, Robert J Laliberte, Jing Wang, Nuno Matos Costa, Petros Grivas
Institutions: St Bartholomew's Hospital, Queen Mary University of London, Barts Cancer Institute, Samsung Medical Center, Sungkyunkwan University, Centre Jean Bernard, Azienda Ospedaliera S.Maria, Hospital Universitario Virgen del Rocío, Macquarie University, Université Paris-Saclay, Institut Gustave Roussy, University Health Network, Princess Margaret Cancer Centre, Yamagata University, Weill Cornell Medicine, Beth Israel Deaconess Medical Center, Harvard University, Inova Fairfax Hospital, Yale Cancer Center, Pfizer (United States), Pfizer (Portugal), Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W4213072175